Skeletal formula of melitracen
Ball-and-stick model of the melitracen molecule
Clinical data
Trade namesAdaptol, Dixeran, Melixeran, Thymeol, Trausabun
AHFS/Drugs.comInternational Drug Names
Routes of
Oral, intramuscular injection
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
  • 3-(10,10-dimethylanthracen-9(10H)-ylidene)-N,N-dimethylpropan-1-amine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.023.507 Edit this at Wikidata
Chemical and physical data
Molar mass291.438 g·mol−1
3D model (JSmol)
  • c3ccc2c(/C(c1c(cccc1)C2(C)C)=C/CCN(C)C)c3
  • InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3 checkY
 ☒NcheckY (what is this?)  (verify)

Melitracen (brand names Melixeran, Trausabun) is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety.[1][2][3][4] In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol.[5][6][7][8]

The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.[9][10]

See also


  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  2. ^ Rhodes PH (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
  3. ^ O'Neil MJ (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
  4. ^ Holenz J, Díaz JL, Buschmann H (2007). "Marketed Drugs and Drugs in DevelopmentVela". In JM, Buschmann H, Holenz J, Párraga A, Torrens A (eds.). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.
  5. ^ Muller NF, Dessing RP (1998). European Drug Index (4th ed.). Boca Raton: CRC Press. ISBN 3-7692-2114-1.
  6. ^ Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica. 83 (5): 525–539. PMID 6670581.
  7. ^ Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia. 8 (2): 37–38. PMID 3917005.
  8. ^ Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, Sharara AI (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics. 27 (11): 1148–1155. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614. S2CID 40714136.
  9. ^ Aronson JK (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 978-0-444-53266-4.
  10. ^ Krapcho J (1970). "Antidepressives and Stimulants". Annual Reports in Medicinal Chemistry. Vol. 5. Boston: Academic Press. ISBN 0-12-040505-9.